A detailed history of Cm Management, LLC transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Cm Management, LLC holds 90,000 shares of GANX stock, worth $115,200. This represents 0.29% of its overall portfolio holdings.

Number of Shares
90,000
Previous 90,000 -0.0%
Holding current value
$115,200
Previous $294,000 15.31%
% of portfolio
0.29%
Previous 0.24%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 08, 2023

SELL
$3.18 - $5.16 $63,600 - $103,200
-20,000 Reduced 18.18%
90,000 $434,000
Q4 2022

Feb 09, 2023

SELL
$2.89 - $3.29 $43,350 - $49,350
-15,000 Reduced 12.0%
110,000 $344,000
Q1 2022

May 09, 2022

BUY
$3.15 - $5.59 $110,250 - $195,650
35,000 Added 38.89%
125,000 $511,000
Q4 2021

Feb 02, 2022

BUY
$5.3 - $9.24 $136,066 - $237,218
25,673 Added 39.91%
90,000 $489,000
Q3 2021

Nov 08, 2021

BUY
$7.01 - $10.26 $380,832 - $557,395
54,327 Added 543.27%
64,327 $479,000
Q2 2021

Aug 10, 2021

BUY
$8.96 - $15.8 $89,600 - $158,000
10,000 New
10,000 $100,000

Others Institutions Holding GANX

About Gain Therapeutics, Inc.


  • Ticker GANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,883,400
  • Market Cap $15.2M
  • Description
  • Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...
More about GANX
Track This Portfolio

Track Cm Management, LLC Portfolio

Follow Cm Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cm Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cm Management, LLC with notifications on news.